October 25, 2022
JACKSONVILLE, Fla. — Johnson & Johnson Vision’s ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management have officially received approval from Health Canada. These orthokeratology lenses are worn overnight for the control of myopia and are specifically designed to match a patient’s eye based on its unique corneal shape and prescription to temporarily reshape the cornea.1-5 This approval follows Health Canada’s approval of ACUVUE Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management in September 2021.
“Johnson & Johnson Vision is helping to address the dramatically increasing rates of myopia by bringing forward innovate products, services and solutions to help control the disease and give families a chance at better eye health in the future,” said Chandra Mickles, OD, MS, FAAO, FSLS, North America Professional Education Lead, Myopia, Johnson & Johnson Vision.6 “With Abiliti Overnight lenses and Abiliti 1-Day lenses, we are adding to our growing suite of Abiliti products to help change the trajectory of myopia.”
Clinical studies have shown Abiliti Overnight lenses are a successful option for controlling the progression of myopia.7-9 The lenses are simple to prescribe by inputting the patient’s refraction, iris diameter, and corneal topography data into the FitAbiliti software, which evaluates and recommends a lens with a first fit success rate of approximately 90%.10,11 Abiliti Overnight lenses will be available in two different contact lens designs: ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management, and ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management for Astigmatism.12
Overnight lenses are now available in select parts of Canada. Families and eye care professionals who want more information can visit www.seeyourabiliti.com.
References
1 As of September 19, 2022, based on publicly available resources
2 Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, et al. Short-term changes in ocular biometry and refraction after discontinuation of long-term orthokeratology. Eye Contact Lens. 2014;40(2):84-90. doi: 10.1097/ICL.0000000000000014.
3 Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). Contact Lens Anterior Eye. 2017;40(2):82-87. doi: 10.1016/j.clae.2016.12.002.
4 Lau JK, Vincent SJ, Cheung SW, et al. The influence of orthokeratology compression factor on ocular higher-order aberrations. Clin Exp Optom. 2020;103(1):123-128. doi: 10.1111/cxo.12933.
5 Wan K, Lau JK, Cheung SW, et al. Refractive and corneal responses of young myopic children to short-term orthokeratology treatment with different compression factors. Contact Lens Anterior Eye. 2020;43(1):65-72. doi: 10.1016/j.clae.2019.10.134.
6 Chandra Mickles, OD, MS, FAAO, FSLS, is an employee of Johnson & Johnson Vision Care, Inc., with oversight of North America Professional Education for Myopia for the Vision Care organization.
7 Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci [Internet]. 2012/09/13. 2012;53(11):7077–85.
8 Chen C, Cheung SW, Cho P. Myopia control using toric orthokeratology (TO-SEE study). Invest Ophthalmol Vis Sci [Internet]. 2013/09/05. 2013;54(10):6510–7.
9 Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Orthokeratology vs. spectacles: adverse events and discontinuations. Optom Vis Sci. 2012 Aug;89(8):1133-9.
10 Final lens fit is determined by the ECP — software is for decision support only.
11 The Johnson & Johnson MedTech Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s MedTech segment.
12 Johnson & Johnson MedTech comprises the surgery, orthopedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.
